Logo
CustomersBlogPricingDemo
SIGN UP NOWBOOK A DEMO

What is the Fiscal Year for Roivant?

Date: November 13, 2026


Roivant's current fiscal year starts on April 1, 2026, and ends on March 31, 2027. Their current quarter is Q3, which ends on December 31, 2026.

Current Fiscal Year Overview

Fiscal Year Start
April 1, 2026
Fiscal Year End
March 31, 2027
Current Quarter
Q3
Current Quarter End
December 31, 2026

Quarterly Breakdown

Q1

Apr 1, 2026 – Jun 30, 2026

Q2

Jul 1, 2026 – Sep 30, 2026

Q3

Oct 1, 2026 – Dec 31, 2026

Q4

Jan 1, 2027 – Mar 31, 2027

Company Information

Headquarters

New York, New York

Industry

Biotechnology

Stock Symbol

ROIV

Website
http://www.roivant.com
Description

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.


Use Salesmotion for Account Data and Insights

Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Roivant and uncover key business information that drives smarter conversations.

Book a demo today to strengthen your sales strategy with powerful data and actionable insights.

BOOK A DEMO